Abstract
Cystatin C (CysC), a cysteine protease inhibitor, has been widely proven to be a highly sensitive biomarker to predict the kidney function. The similarity of the renal and cerebral small vessels has awakened a surge of studies suggesting that CysC plays a key role in various cerebrovascular disorders. This review focuses on four major mechanisms of CysC in a variety of cerebrovascular diseases. (1) The property of the CysC Leu-68-Gln (L68Q) variant to aggregate and the property of the wild type CysC protein to co-aggregate with Amyloid-β (Aβ); (2) The disruption of equilibrium between CysC and related cysteine proteases; (3) The function of CysC as an inflammatory inducing factor; (4) The ability of CysC to induce autophagy. The combination of these CysC properties provides a well-supported novel biomarker for cerebrovascular diseases.
Keywords: CysC, cerebrovascular diseases, cerebral amyloid angiopathy (CAA), cerebral aneurysms (CAs), subarachnoid hemorrhage (SAH), ischemic stroke, cerebral small vascular diseases (CSVDs), vascular dementia (VD).
Current Neurovascular Research
Title:Cystatin C in Cerebrovascular Disorders
Volume: 14 Issue: 4
Author(s): Yaru Zhang and Li Sun*
Affiliation:
- Department of Neurology and Neuroscience Center, The First Hospital of Jilin University, Changchun,China
Keywords: CysC, cerebrovascular diseases, cerebral amyloid angiopathy (CAA), cerebral aneurysms (CAs), subarachnoid hemorrhage (SAH), ischemic stroke, cerebral small vascular diseases (CSVDs), vascular dementia (VD).
Abstract: Cystatin C (CysC), a cysteine protease inhibitor, has been widely proven to be a highly sensitive biomarker to predict the kidney function. The similarity of the renal and cerebral small vessels has awakened a surge of studies suggesting that CysC plays a key role in various cerebrovascular disorders. This review focuses on four major mechanisms of CysC in a variety of cerebrovascular diseases. (1) The property of the CysC Leu-68-Gln (L68Q) variant to aggregate and the property of the wild type CysC protein to co-aggregate with Amyloid-β (Aβ); (2) The disruption of equilibrium between CysC and related cysteine proteases; (3) The function of CysC as an inflammatory inducing factor; (4) The ability of CysC to induce autophagy. The combination of these CysC properties provides a well-supported novel biomarker for cerebrovascular diseases.
Export Options
About this article
Cite this article as:
Zhang Yaru and Sun Li *, Cystatin C in Cerebrovascular Disorders, Current Neurovascular Research 2017; 14 (4) . https://dx.doi.org/10.2174/1567202614666171116102504
DOI https://dx.doi.org/10.2174/1567202614666171116102504 |
Print ISSN 1567-2026 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-5739 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
The TT allele of rs405509 synergizes with APOE ε4 in the impairment of cognition and its underlying default mode network in non-demented elderly
Current Alzheimer Research Antioxidant Activity of Galantamine and Some of its Derivatives
Current Medicinal Chemistry Cerebrovascular Profile Assessment in Parkinson's Disease Patients
CNS & Neurological Disorders - Drug Targets Hypertension in Hemodialysis Patients
Current Hypertension Reviews On the Interaction of β-Amyloid Peptides and α7-Nicotinic Acetylcholine Receptors in Alzheimer’s Disease
Current Alzheimer Research Endothelial Progenitor Cells in Prehypertension
Current Pharmaceutical Design Identifying S100B as a Biomarker and a Therapeutic Target For Brain Injury and Multiple Diseases
Current Medicinal Chemistry SPECT Radiopharmaceuticals for Dementia
Current Radiopharmaceuticals A Case of Ischemic Stroke in Acute Promyelocytic Leukemia at Initial Presentation: Relevance of All-Trans Retinoic Acid Treatment
Cardiovascular & Hematological Disorders-Drug Targets Childhood Hypertension and Effects on Cognitive Functions: Mechanisms and Future Perspectives
CNS & Neurological Disorders - Drug Targets Fibrinolytic Enzymes From Extremophilic Microorganisms in the Development of New Thrombolytic Therapies: Technological Prospecting
Recent Patents on Biotechnology Potential Therapeutic Benefits of Sodium-Glucose Cotransporter 2 Inhibitors in the Context of Ischemic Heart Failure: A State-of-the-Art Review
Cardiovascular & Hematological Agents in Medicinal Chemistry Triptan-Induced Torsades de Pointes and Ventricular Fibrillation Cardiac Arrest: Case Report and Review of the Literature
Current Drug Safety The Molecular Genetics of Migraine: Toward the Identification of Responsible Genes
Current Genomics Aging in Down Syndrome and the Development of Alzheimer’s Disease Neuropathology
Current Alzheimer Research Neuropathological Correlates of Cerebral Multimorbidity
Current Alzheimer Research Dyslipidemia, Metabolic Syndrome and Vascular Disease Among Asian Indians
Vascular Disease Prevention (Discontinued) Nanoemulsions for Improved Efficacy of Phytotherapeutics- A Patent Perspective
Recent Patents on Nanotechnology CHF5074 Reduces Biomarkers of Neuroinflammation in Patients with Mild Cognitive Impairment: A 12-Week, Double-Blind, Placebo- Controlled Study
Current Alzheimer Research Stroke History is an Independent Risk Factor for Poor Prognosis in Ischemic Stroke Patients: Results from a Large Nationwide Stroke Registry
Current Neurovascular Research